Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review

被引：1

作者：

Zambelli, Alberto ^{[1
,2
]}

Cortesi, Laura ^{[3
]}

Gaudio, Mariangela ^{[1
,2
]}

Arpino, Grazia ^{[4
]}

Bianchini, Giampaolo ^{[5
,6
]}

Caruso, Francesco ^{[7
]}

Cinieri, Saverio ^{[8
,9
]}

Curigliano, Giuseppe ^{[10
,11
]}

Del Mastro, Lucia ^{[12
,13
]}

De Placido, Sabino ^{[14
]}

Fabi, Alessandra ^{[15
]}

Fortunato, Lucio ^{[16
]}

Generali, Daniele ^{[17
,18
]}

Gennari, Alessandra ^{[19
,20
]}

Gori, Stefania ^{[21
]}

Grandi, Giovanni ^{[22
]}

Guarneri, Valentina ^{[23
,24
]}

Klinger, Marco ^{[25
]}

Livi, Lorenzo ^{[26
]}

Marchio, Caterina ^{[27
,28
]}

Palumbo, Isabella ^{[29
,30
]}

Panizza, Pietro ^{[31
]}

Pravettoni, Gabriella ^{[32
]}

Pruneri, Giancarlo ^{[33
,34
]}

Puglisi, Fabio ^{[35
,36
]}

Sapino, Anna ^{[28
]}

Tinterri, Corrado ^{[1
,37
]}

Turchetti, Daniela ^{[38
,39
]}

De Laurentiis, Michelino ^{[40
]}

机构：

[1] Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini 4, I-20090 Milan, Italy

[2] Humanitas Clin & Res Ctr, IRCCS, Humanitas Canc Ctr, Via Manzoni 56, I-20089 Milan, Italy

[3] Univ Hosp Modena, Dept Oncol & Hematol, Via Pozzo 71, I-41124 Modena, Italy

[4] Univ Federico II, Dept Clin Med & Surg, Naples, Italy

[5] IRCCS San Raffaele Hosp, Dept Med Oncol, Milan, Italy

[6] Univ Vita Salute San Raffaele, Milan, Italy

[7] Humanitas Hosp, Breast Unit Surg, Via Vittorio Emanuele da Bormida 64, Catania, Italy

[8] Osped Perrino, UOC Oncol Med & Breast Unit, Brindisi, Italy

[9] Fdn AIOM, Milan, Italy

[10] Ist Europeo Oncol, IRCCS, Milan, Italy

[11] Univ Milan, Dipartimento Oncol Emato Oncol, Milan, Italy

[12] Univ Genoa, Sch Med, Dept Internal Med & Med Specialties DiMI, Genoa, Italy

[13] Osped Policlin San Martino, Dept Med Oncol, UO Clin Oncol Med, IRCCS, Genoa, Italy

[14] Univ Naples Federico II, Dept Clin Med & Surg, Naples, Italy

[15] Fdn Policlin Univ A Gemelli IRCCS, Precis Med Unit Senol, Rome, Italy

[16] San Giovanni Addolorata Hosp, Breast Ctr, Dept Surg, Rome, Italy

[17] Azienda Socio Sanit Terr Cremona, Breast Canc Unit, Cremona, Italy

[18] Univ Trieste, Dept Med Surg & Hlth Sci, Trieste, Italy

[19] Univ Piemonte Orientale, Dept Traslat Med, Novara, Italy

[20] Maggiore Univ Hosp, Div Med Oncol, Novara, Italy

[21] IRCCS Sacro Cuore Don Calabria, Med Oncol, Negrar Di Valpolicella, VR, Italy

[22] Univ Modena & Reggio Emilia, Dept Med & Surg Sci Mother Child & Adult, Azienda Osped Univ Modena, Modena, Italy

[23] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy

[24] Ist Oncol Veneto IRCCS, Oncol2, Padua, Italy

[25] Univ Milan, Humanitas Clin & Res Hosp, Reconstruct & Aesthet Plast Surg Sch, Dept Med Biotechnol & Translat Med BIOMETRA,Plast, Milan, Italy

[26] Univ Florence, Radiat Oncol Unit, Azienda Ospedaliero Universitaria Careggi, Florence, Italy

[27] Univ Turin, Dept Med Sci, Turin, Italy

[28] Candiolo Canc Inst, Pathol Unit, FPO IRCCS, Candiolo, Italy

[29] Univ Perugia, Radiat Oncol Sect, Perugia, Italy

[30] Perugia Gen Hosp, Perugia, Italy

[31] IRCCS Osped San Raffaele, Breast Imaging Unit, Milan, Italy

[32] Univ Milan, Ist Europeo Oncol, Dept Oncol & Haematol, Appl Res Div Cognit & Psychol Sci,IRCCS, Milan, Italy

[33] Fdn IRCCS, Ist Nazl Tumori, Dept Adv Diagnost, Milan, Italy

[34] Univ Milan, Sch Med, Dept Oncol & Hematooncol, Milan, Italy

[35] Univ Udine, Dept Med, Udine, Italy

[36] Ctr riferimento Oncol, Dept Med Oncol, Unit Med Oncol & Canc Prevent, IRCCS, Aviano, Italy

[37] Humanitas Res Hosp, Breast Unit, Milan, Italy

[38] Univ Bologna, Dept Med & Surg Sci DIMEC, Bologna, Italy

[39] IRCCS Azienda Osped Univ Bologna, Med Genet Unit, Bologna, Italy

[40] Ist Nazl Tumori IRCCS Fdn G Pascale, Div Breast Med Oncol, Naples, Italy

来源：

CANCER TREATMENT REVIEWS | 2024年 / 130卷

关键词：

Breast cancer; BRCA; Genetic testing; Olaparib; PARP-inhibitor; PEMBROLIZUMAB PLUS CHEMOTHERAPY; MUTATION CARRIERS; OPEN-LABEL; RISK; SURVIVAL; OLAPARIB; OVARIAN; GENES;

D O I：

10.1016/j.ctrv.2024.102815

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The introduction of PARP inhibitors has revolutionized the management and treatment of patients with pathogenic germline variants of BRCA1/2 who have developed breast cancer. The implementation of PARP inhibitors in clinical settings can be challenging due to their overlapping indications with other drugs, including both recently approved medications and those with proven efficacy. This study utilized the Delphi method to present the first Italian consensus regarding genetic testing, the use of PARP inhibitors in both early and metastatic settings, and strategies for managing the potential toxicity of these novel drugs. The Panel unanimously agreed on various issues, including the timing, techniques, and patient characteristics for BRCA1/2 genetic testing, and the appropriate placement of PARP inhibitors in the treatment algorithm for both early and advanced breast cancer. Nevertheless, some areas of divergence became evident, particularly regarding the use of axillary surgery for therapeutic purposes and the application of hormone replacement therapy in cases of bilateral mastectomy and risk-reducing salpingo-oophorectomy for patients treated for triple negative breast cancer. Additional research is needed in these particular domains to improve the care of patients with breast cancer who bear an increased genetic risk.

引用

页数：10

共 57 条

[51] EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy
Schmidt, Marjanka K.
Kelly, Jennifer E.
Bredart, Anne
Cameron, David A.
de Boniface, Jana
Easton, Douglas F.
Offersen, Birgitte, V
Poulakaki, Fiorita
Rubio, Isabel T.
Sardanelli, Francesco
Schmutzler, Rita
Spanic, Tanja
Weigelt, Britta
Rutgers, Emiel J. T.
[J]. EUROPEAN JOURNAL OF CANCER, 2023, 181 : 79 - 91
[52] Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial
Senkus, Elzbieta
Delaloge, Suzette
Domchek, Susan M.
Conte, Pierfranco
Im, Seock-Ah
Xu, Binghe
Armstrong, Anne
Masuda, Norikazu
Fielding, Anitra
Robson, Mark
Tung, Nadine
[J]. INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (04) : 803 - 814
[53] Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline
Sessa, C.
Balmana, J.
Bober, S. L.
Cardoso, M. J.
Colombo, N.
Curigliano, G.
Domchek, S. M.
Evans, D. G.
Fischerova, D.
Harbeck, N.
Kuhl, C.
Lemley, B.
Levy-Lahad, E.
Lambertini, M.
Ledermann, J. A.
Loibl, S.
Phillips, K. -A.
Paluch-Shimon, S.
[J]. ANNALS OF ONCOLOGY, 2023, 34 (01) : 33 - 47
[54] Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Tutt, Andrew
Tovey, Holly
Cheang, Maggie Chon U.
Kernaghan, Sarah
Kilburn, Lucy
Gazinska, Patrycja
Owen, Julie
Abraham, Jacinta
Barrett, Sophie
Barrett-Lee, Peter
Brown, Robert
Chan, Stephen
Dowsett, Mitchell
Flanagan, James M.
Fox, Lisa
Grigoriadis, Anita
Gutin, Alexander
Harper-Wynne, Catherine
Hatton, Matthew Q.
Hoadley, Katherine A.
Parikh, Jyoti
Parker, Peter
Perou, Charles M.
Roylance, Rebecca
Shah, Vandna
Shaw, Adam
Smith, Ian E.
Timms, Kirsten M.
Wardley, Andrew M.
Wilson, Gregory
Gillett, Cheryl
Lanchbury, Jerry S.
Ashworth, Alan
Rahman, Nazneen
Harries, Mark
Ellis, Paul
Pinder, Sarah E.
Bliss, Judith M.
[J]. NATURE MEDICINE, 2018, 24 (05) : 628 - +
[55] Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Tutt, Andrew N. J.
Garber, Judy E.
Kaufman, Bella
Viale, Giuseppe
Fumagalli, Debora
Rastogi, Priya
Gelber, Richard D.
de Azambuja, Evandro
Fielding, Anitra
Balmana, Judith
Domchek, Susan M.
Gelmon, Karen A.
Hollingsworth, Simon J.
Korde, Larissa A.
Linderholm, Barbro
Bandos, Hanna
Senkus, E.
Suga, Jennifer M.
Shao, Z.
Pippas, Andrew W.
Nowecki, Zbigniew
Huzarski, Tomasz
Ganz, Patricia A.
Lucas, Peter C.
Baker, Nigel
Loibl, Sibylle
McConnell, Robin
Piccart, Martine
Schmutzler, Rita
Steger, Guenther G.
Costantino, Joseph P.
Arahmani, Amal
Wolmark, Norman
McFadden, Eleanor
Karantza, Vassiliki
Lakhani, Sunil R.
Yothers, Greg
Campbell, Christine
Geyer, Charles E.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (25) : 2394 - 2405
[56] Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments
Valenza, Carmine
Trapani, Dario
Gandini, Sara
Sposetti, Caterina
Bielo, Luca Boscolo
Marra, Antonio
Giarratano, Tommaso
Favero, Diletta
Cortesi, Laura
Moscetti, Luca
Pistelli, Mirco
Berardi, Rossana
Zambelli, Alberto
Lambertini, Matteo
Del Mastro, Lucia
Guarneri, Valentina
Vernieri, Claudio
Curigliano, Giuseppe
[J]. EUROPEAN JOURNAL OF CANCER, 2023, 190
[57] Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment The SYSUCC-001 Randomized Clinical Trial
Wang, Xi
Wang, Shu-Sen
Huang, Heng
Cai, Li
Zhao, Li
Peng, Rou-Jun
Lin, Ying
Tang, Jun
Zeng, Jian
Zhang, Le-Hong
Ke, Yong-Li
Wang, Xian-Ming
Liu, Xin-Mei
Chen, Qian-Jun
Zhang, An-Qin
Xu, Fei
Bi, Xi-Wen
Huang, Jia-Jia
Li, Ji-Bin
Pang, Dan-Mei
Xue, Cong
Shi, Yan-Xia
He, Zhen-Yu
Lin, Huan-Xin
An, Xin
Xia, Wen
Cao, Ye
Guo, Ying
Su, Yan-Hong
Hua, Xin
Wang, Xin-Yue
Hong, Ruo-Xi
Jiang, Kui-Kui
Song, Chen-Ge
Huang, Zhang-Zan
Shi, Wei
Zhong, Yong-Yi
Yuan, Zhong-Yu
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (01): : 50 - 58

← 1 2 3 4 5 6 →